PDF(Pubmed)
Abstract：
BACKGROUND: Hyperreactive malarial splenomegaly (HMS) is one of the main causes of massive splenomegaly in malaria-endemic zones. Diagnosis is often challenging in Bobo-Dioulasso. This study aimed to describe the clinical and socio-demographic profile, and the reasons for delay in the diagnosis of HMS cases recorded in the Medicine and Medical Specialties wards of Souro Sanou Teaching hospital.
METHODS: A retrospective descriptive study was conducted from August 2022 by focusing on HMS cases diagnosed in the Infectious Diseases and Clinical Hematology wards of Souro Sanou Teaching Hospital.
RESULTS: Overall, 65 patients met our inclusion criteria over the 12-year period. Burkinabe nationals and have been residing in Burkina Faso since their birth. 79% (79%) of the patients were seen for medical consultation with the reason for consultation being a voluminous mass in the left hypochondrium. Indigence, self-medication, and lack of information were essential elements in late diagnosis of HMS in Bobo-Dioulasso. All patients were treated with a single tablet of Artemether (80 mg) and Lumefantrine (480 mg) in the morning and evening for 3 days, followed by sulfadoxine-pyrimethamine per week. Nine months later, patients were clinically asymptomatic.
CONCLUSIONS: This study provides a database on hyperreactive malarial splenomegaly (HMS) in the south-west region of Burkina Faso. Rapid and accurate diagnosis of the disease and appropriate use of effective antimalarial drugs would significantly reduce the burden of HMS in Sub-Saharan African countries.
METHODS: A retrospective descriptive study was conducted from August 2022 by focusing on HMS cases diagnosed in the Infectious Diseases and Clinical Hematology wards of Souro Sanou Teaching Hospital.
RESULTS: Overall, 65 patients met our inclusion criteria over the 12-year period. Burkinabe nationals and have been residing in Burkina Faso since their birth. 79% (79%) of the patients were seen for medical consultation with the reason for consultation being a voluminous mass in the left hypochondrium. Indigence, self-medication, and lack of information were essential elements in late diagnosis of HMS in Bobo-Dioulasso. All patients were treated with a single tablet of Artemether (80 mg) and Lumefantrine (480 mg) in the morning and evening for 3 days, followed by sulfadoxine-pyrimethamine per week. Nine months later, patients were clinically asymptomatic.
CONCLUSIONS: This study provides a database on hyperreactive malarial splenomegaly (HMS) in the south-west region of Burkina Faso. Rapid and accurate diagnosis of the disease and appropriate use of effective antimalarial drugs would significantly reduce the burden of HMS in Sub-Saharan African countries.
摘要：
背景：高反应性疟疾脾肿大（HMS）是疟疾流行区大量脾肿大的主要原因之一。Bobo-Dioulasso的诊断通常具有挑战性。这项研究旨在描述临床和社会人口统计学特征，以及SouroSanou教学医院医学和医学专科病房记录的HMS病例诊断延迟的原因。
方法：从2022年8月开始进行回顾性描述性研究，重点是在SouroSanou教学医院的传染病和临床血液科病房诊断的HMS病例。
结果：总体而言，在12年期间，有65例患者符合我们的纳入标准。布基纳法索国民，自出生以来一直居住在布基纳法索。79％（79％）的患者接受了医疗咨询，咨询的原因是左下软骨中的大量肿块。Indigence,自我药疗,缺乏信息是Bobo-Dioulasso晚期诊断HMS的基本要素。所有患者均在早晚服用Artemether（80mg）和Lumefantrine（480mg）单片治疗3天，其次是磺胺多辛-乙胺嘧啶每周。九个月后,患者临床无症状.
结论：本研究提供了布基纳法索西南地区高反应性疟疾脾肿大（HMS）的数据库。在撒哈拉以南非洲国家，快速准确地诊断该疾病并适当使用有效的抗疟药物将大大减少HMS的负担。
方法：从2022年8月开始进行回顾性描述性研究，重点是在SouroSanou教学医院的传染病和临床血液科病房诊断的HMS病例。
结果：总体而言，在12年期间，有65例患者符合我们的纳入标准。布基纳法索国民，自出生以来一直居住在布基纳法索。79％（79％）的患者接受了医疗咨询，咨询的原因是左下软骨中的大量肿块。Indigence,自我药疗,缺乏信息是Bobo-Dioulasso晚期诊断HMS的基本要素。所有患者均在早晚服用Artemether（80mg）和Lumefantrine（480mg）单片治疗3天，其次是磺胺多辛-乙胺嘧啶每周。九个月后,患者临床无症状.
结论：本研究提供了布基纳法索西南地区高反应性疟疾脾肿大（HMS）的数据库。在撒哈拉以南非洲国家，快速准确地诊断该疾病并适当使用有效的抗疟药物将大大减少HMS的负担。
